UCI 趙 Chao Family Comprehensive Cancer Center

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:
Blake Johnson

Clinical Research Coordinators:
Stephanie Osorio
Judit Castellanos
Kelsey McAbee
Regan Dagenhart
Harleen Mehrok
Alice Ting
Michael Kunicki
Georgina Alvarez-Diaz

Data Coordinators:
Heather Franson
Neha Ashraf
An To

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Myeloproliferative Neoplasm

Front Line

ETCTN 10538
Venetoclax+ASTX727 (All oral therapy) for CMML, MDS/MPN with excess blasts

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: BCL-2 selective inhibitor

UCI 24-121
ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 0/5

Coord: TBD
Mechanism: cytidine deaminase inhibitor

Observational Study

UCI 23-32
Dissecting the mechanism of Interferon Alpha (IFN) response in MPN

Coord: N/A
Mechanism: observational study

Supportive Care

UCI 20-50
N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 13/27

Coord: Kelsey McAbee
Mechanism: Mucolytic agent (cysteine and GSH precursor)

Myelodysplastic Syndrome

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Low-Risk

Molecularly-Driven

HSCT

High-Risk

UCI 24-121
ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 0/5

Coord: TBD
Mechanism: cytidine deaminase inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

High-Risk

UCI 22-151
LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 5/8

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

UCI 23-113
Oral GLB-001 in patients w/ R/R AML or high-risk MDS

Accrual: 2/7

Coord: Stephanie Osorio
Mechanism: Selective molecular glue degrader

Low-Risk

UCI 21-239
IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual:1/5

Coord: Stephanie Osorio
Mechanism: IRAk1/4 inhibitor

Molecularly-Driven

Myelodysplastic Syndrome

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Acute Myeloid Leukemia

Intensive

ETCTN-10596
SNDX-5613 + Daunorubicin and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia (NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged)

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

Non-Intensive

ETCTN-10630
Ladademstat in Combination with Venetoclax and Azacitidine in Patients with Post MDS Transformation to AML

Accrual: 1/7

Coord: Stephanie Osorio
Mechanism: LSD1 inhibitor

UCI 24-121
ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 0/5

Coord: TBD
Mechanism: cytidine deaminase inhibitor

KMT2A-r/NPM1-m

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 7/10

Coord: Stephanie Osorio
Mechanism: menin inhibitor

FLT3 mutation

UCI 21-216
Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 2/5

Coord: Stephanie Osorio
Mechanism: FLT3 inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

2nd Line+

UCI 23-113
Oral GLB-001 in patients w/ R/R AML or high-risk MDS

Accrual: 2/7

Coord: Stephanie Osorio
Mechanism: Selective molecular glue degrader

UCI 22-151
LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 5/8

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

UCI 22-81
HM43239 in patients w/ R/R AML
Accrual: 1/6

Coord: Stephanie Osorio
Mechanism: FLT3 inhibitor

UCI 24-48
DFP-10917+Venetoclax in R/R AML
Accrual: 4/5

Coord: Stephanie Osorio
Mechanism: Deoxycytidine nucleoside analogue (DNA synthesis inhibitor)

UCI 23-154
Ziftomenib combinations for the KMT2A-rearranged/NPM1 mutant R/R AML

Accrual: 2/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

Acute Myeloid Leukemia

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 7/10

Coord: Stephanie Osorio
Mechanism: menin inhibitor

Salvage Therapy

Maintenance

High-Risk, HSCT

Acute Lymphoblastic Leukemia

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

EA9181
Steroids +TIKI w/ chemotherapy or Blinatumomab for BCR-ABL positive adult patients

Accrual 14/35

Coord: Judit Castellanos
Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

Ph- only

Age 22-55 years & BMI <35kg/m2

UCI 22-125 (closed to accrual)
Calaspargase pegol for tx of adults 22-55y/o w/ newly diagnosed Ph- ALL

Accrual: 0/5

Coord: Judit Castellanos
Mechanism: PEGylated conjugate L-asparaginase

Age ≥ 18 years & < 40 years, CD22+ (≥ 20%)

A041501 (Suspended)
Addition of Inotuzumab Ozogamicin to frontline therapy in young adults (18-39y/o)

Accrual: 10/15

Coord: Judit Castellanos
Mechanism: conjugated anti-CD22 monoclonal antibody

Age 5 to <30 years & High Risk ALL

UCI 21-14
Levocarnitine for Asparaginase hepatoxicity in ALL patients

Accrual: 0/5 (opened 11/3/23)

Coord: Judit Castellanos
Mechanism: Oxidative stress reducer & inflammatory modulator

Observational

UCI 21-236
Addressing the Hispanic Cancer Disparity in B Cell Acute Lymphoblastic Leukemia
Accrual: NA

Coord: NA
Mechanism: Observational

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

CD22+ (≥ 20%)

A041703

Inotuzumab Ozogamicin followed by Blinatumomab for ph- CD22-positive newly diagnosed or R/R ALL patients

Accrual: 2/5 (only open for R/R)

Coord: Judit Castellanos

Mechanism: antibody-drug conjugate combining a monoclonal antibody targeting CD22 on B-lymphoblast with the cytoxic agents

CR w/ MRD+

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

High-Risk

S1925
Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 4/10

Coord: Kelsey McAbee
Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

Front Line

UCI 23-156
Sonrotoclax (BGB-11417) + Zanubrutinib (BGB-3111) v.s. Venetoclax +Obinutuzumab
Accrual: 3/7

Coord: Kelsey McAbee
Mechanism: BTK + BCL2 inhibition

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Chronic Lymphocytic Leukemia

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 24-12
Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

2nd Line+

Molecularly-Driven

Cell Therapy

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd Line+

UCI 23-167
Phase I- TERN-701 in patients w/CML

Accrual: 2/5

Coord: Kelsey McAbee
Mechanism: STAMP inhibitor

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Post ASCT

Front Line

Bispecific

UCI 23-158

Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma

Accrual: 1/6 (opened 3/29/24)

Coord: Alice Ting

Mechanism: Bispecific antibody (BCMA x CD3)

High-Risk

ETCTN 10612

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma

Accrual: 5/8 (opened 4/25/24)

Coord: Alice Ting

Mechanism: selective inhibitor of nuclear export

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Maintenance

3rd Line+

CAR-T

UCI 24-02
Descartes-15 in R/R MM
Accrual: 3/5

Coord: Mike Kunicki
Mechanism: CAR-T, BCMA

2nd Line+

UCI 22-190
Teclistamab monotherapy vs. PVD or KD in patients received 1-3 prior lines of therapy

Accrual: 3/6

Coord: Alice Ting
Mechanism: CD3 x BCMA BiTE

Multiple Myeloma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

2nd Line+

Maintenance

3rd Line+

CAR-T

ALLIANCE-A062102
Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in R/R MM
Accrual: 0/5

Coord: Judit Castellanos
Mechanism: cereblon (CRBN) modulating agent

Multiple Myeloma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Front Line

UCI 23-17
Odronextamab (REGN1979) vs. investigator's choice in patient w/ FL

Accrual: 0/5 (3/20/24)

Coord: Regan Dagenhart
Mechanism: Anti-CD20 x Anti-CD3 bispecific antibody

SWOG 2308
MOSUNETUZUMAB VS. RITUXIMAB FOR LOW TUMOR BURDEN FOLLICULAR LYMPHOMA

Accrual: 0/5

Coord: Stephanie Osorio/Judit Castellanos
Mechanism: Anti-CD20 IgG1 kappa antibody

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

Outpatient

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Regan Dagenhart
Mechanism: bite/mab

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

2+ Lines

UCI 24-12

Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

Follicular Lymphoma

Marginal Zone Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

EBV+

2 + Lines

UCI 24-12
Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

Mantle Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

2+ Lines

UCI 24-12
Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

Diffuse Large B-Cell Lymphoma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

75 y/o Older

S1918 (SUSPENDED)
R-miniCHOP w/ or w/o oral Azacititine in patients 75 y/o or older

Accrual: 5/10

Coord: Regan Dagenhart
Mechanism: Oral hypomethylating agent

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Primary Relapsed/Refractory

Secondary Relapsed/Refractory

UCI 20-126
CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/7

Coord: Michael K.
Mechanism: anti-CD19
CHIMERIC ANTIGEN RECEPTOR

Outpatient

Cell Therapy- CRS mgmt

UCI 23-193 (IRB initial approval)
CTO1681 for the Prevention and Treatment of CRS in Patients with DLBCL receiving Chimeric Antigen Receptor T-Cell Therapy
Accrual: 1/5

Coord: Judit Castellanos
Mechanism: PGE2 & PGI2 agonist

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Tertiary Relapsed/Refractory

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Regan Dagenhart
Mechanism: bite/mab

2+ Lines

UCI 24-12
Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

Hodgkin's Lymphoma

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Basket study

COG-AHOD2131
Standard Therapy with Immuno-oncology Therapy for Newly Diagnosed Stage I and II Classical Hodgkin Lymphoma
Accrual: 1/5
Coord: Judit Castellanos/ Stephanie Osorio
Mechanism:

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Basket study

Hodgkin's Lymphoma

Primary Mediastinal B-Cell Lymphoma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

COG ANHL1931
Nivolumab + chemo-immunotherapy

Accrual: 2/5

Coord: Regan Dagenhart
Mechanism: PD1 inhibitor

Primary Mediastinal B-Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Regan Dagenhart
Mechanism: bite/mab

2+ Lines

UCI 24-12
Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Cell Therapy

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL
Accrual: 3/7

Coord: Judit Castellanos
Mechanism: CD19/20 bispecific CAR

2+ Lines

UCI 24-12
Study to Evaluate the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

3rd line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

Cutaneous T-Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

UCI 21-99
ONO-4685 given as monotherapy

Accrual: 4/10

Coord: Regan Dagenhart
Mechanism: CD3-bispecific antibody targeting PD-1

Peripheral T-Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

3rd Line+

UCI 21-99
ONO-4685 given as monotherapy

Accrual: 4/10

Coord: Regan Dagenhart
Mechanism: CD3-bispecific antibody targeting PD-1

Molecularly-Driven

2nd Line+

Open to Accrual | Low Accruing | Pending Activation/Suspended

Allo-SCT Conditioning

UCI 21-90
Risk-ADAPTed conditioning regimen for AHSCT

Accrual: 19/48

Coord: Heme CRCs

Auto-SCT Maintenance

Allo-SCT Supportive Care

UCI 22-188
Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHCT

Accrual: 10/50

Coord: Heme CRCs

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cellular Therapy

CAR-T

UCI 20-126
CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/7

Coord: Michael K.
Mechanism: anti-CD19 CAR-T

UCI 23-114
Safety & Efficacy of IMPT-314, a CD19/20 Bispecific CAR-T in Participants with R/R B-Cell NHL

Accrual: 3/7

Coord: Judit Castellanos
Mechanism: CD19/20 bispecific CAR

UCI 24-02
Descartes-15 in R/R MM

Accrual: 3/5

Coord: Mike K.
Mechanism: CAR-T, BCMA

Supportive Care

UCI 23-193
CTO1681 for the Prevention and Treatment of CRS in Patients with DLBCL receiving CAR-T Therapy

Accrual: 1/5

Coord: Alice Ting
Mechanism: PGE2 & PGI2 agonist

Post CAR-T

S2114
Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 0/6

Coord: Regan Dagenhart
Mechanism: BiTE/mAb

Alliance-A062102
Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

Coord: TBD
Mechanism: Cereblon (CRBN) modulating agent

Open to Accrual | Low Accruing | Pending Activation/Suspended

Supportive Care

UCI 14-03
Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm

UCI 15-65

Effect of candidate blood cancer therapies on normal human lymphocytes

Long-Term FU

UCI 21-184
Long-term safety of CAR-T inpatient w/ heme malignancies

Accrual: 4/5

Coord: Miranda Duron

UCI 24-31
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Accrual: 0/5

Coord: TBD

Open to Accrual | Low Accruing | Pending Activation/Suspended

HLH

UCI 23-189
Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 0/5

Coord: Stephanie Osorio

Other